晚期卵巢浆液性癌伴腹股沟淋巴结转移一例

doi:10.12280/gjfckx.20250035

摘要/Abstract

摘要：

报告1例晚期卵巢癌伴腹股沟淋巴结转移病例。患者因腹胀3个月，自扪及腹部包块2个月就诊，影像学检查提示盆腔巨大肿物及盆腔积液，左侧腹股沟区多发增大淋巴结，多考虑转移，遂行卵巢恶性肿瘤细胞减灭术，术后病理活检提示左侧卵巢高级别浆液性癌ⅣB期、左侧腹股沟淋巴结转移。术后进行静脉化疗，第1周期使用紫杉醇和卡铂进行化疗，第2周期在原有化疗方案基础上添加贝伐珠单抗进行靶向治疗。化疗6个疗程后靶向治疗17个疗程，此后尼拉帕利维持治疗至今，无明显不良反应，未见肿瘤复发和转移。

关键词: 卵巢肿瘤, 淋巴转移, 腹股沟, 抗肿瘤联合化疗方案, 病例报告

Abstract:

A case of advanced ovarian cancer with inguinal lymph node metastasis was reported. The patient presented with abdominal distension for 3 months and self-palpated abdominal mass for 2 months. Imaging examinations revealed a large pelvic masses and pelvic effusion, as well as multiple enlarged lymph nodes in the left inguinal region, which were highly suspected to be metastasis. Subsequently, cytoreductive surgery for ovarian malignant was performed. Postoperative pathological biopsy indicated high-grade serous carcinoma of left ovary, stage ⅣB, with left inguinal lymph node metastasis. Intravenous chemotherapy was performed after surgery. In the first cycle, paclitaxel and carboplatin were used for chemotherapy. In the second cycle, bevacizumab was added to the original chemotherapy regimen for targeted therapy. After 6 cycles of chemotherapy and 17 cycles of targeted therapy, maintenance therapy with niraparib has been continued to date. There have been no obvious adverse reactions, and no tumor recurrence or metastasis has been observed.

Key words: Ovarian neoplasms, Lymphatic metastasis, Groin, Antineoplastic combined chemotherapy protocols, Case reports

陈家玉, 邵亚雯, 彭皓晨, 吴珍珍. 晚期卵巢浆液性癌伴腹股沟淋巴结转移一例[J]. 国际妇产科学杂志, 2025, 52(3): 357-360.

CHEN Jia-yu, SHAO Ya-wen, PENG Hao-chen, WU Zhen-zhen. A Case of Advanced Ovarian Serous Carcinoma with Inguinal Lymph Node Metastasis[J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 357-360.

图/表 2

参考文献 21

[1]	Ferrero A, Ditto A, Giorda G, et al. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study[J]. Eur J Surg Oncol, 2014, 40(7):891-898. doi: 10.1016/j.ejso.2013.11.026. pmid: 24378007
[2]	Kanchustambham V, Saladi S. Adenocarcinoma of the Lung With Inguinal Lymph Node Metastasis[J]. Cureus, 2021, 13(3):e13658. doi: 10.7759/cureus.13658.
[3]	Eoh KJ, Lee JY, Yoon JW, et al. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery[J]. Oncotarget, 2017, 8(23):37807-37816. doi: 10.18632/oncotarget.13696. pmid: 27906676
[4]	Burghardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer[J]. Gynecol Oncol, 1991, 40(2):103-106. doi: 10.1016/0090-8258(91)90099-q. pmid: 2010101
[5]	张瑞钰, 梁斯晨, 王志启, 等. 卵巢上皮性癌的淋巴结转移规律及前哨淋巴结检测技术在早期患者中应用的研究进展[J]. 中华妇产科杂志, 2021, 56(9):656-659. doi: 10.3760/cma.j.cn112141-20210627-00343.
[6]	Metwally IH, Zuhdy M, Hassan A, et al. Ovarian cancer with metastatic inguinal lymphadenopathy: A case series and literature review[J]. J Egypt Natl Canc Inst, 2017, 29(2):109-114. doi: 10.1016/j.jnci.2017.01.003. pmid: 28258913
[7]	Bacalbasa N, Balescu I, Balalau C, et al. Normal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases - A Case Report and Literature Review[J]. In Vivo, 2018, 32(2):385-389. doi: 10.21873/invivo.11250. pmid: 29475925
[8]	Yang XJ, Zheng FY, Xu YS, et al. Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: a case study and review of the literature[J]. J Ovarian Res, 2014,7:20. doi: 10.1186/1757-2215-7-20.
[9]	Kleppe M, Kraima AC, Kruitwagen RF, et al. Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer[J]. Int J Gynecol Cancer, 2015, 25(8):1405-1414. doi: 10.1097/IGC.0000000000000514. pmid: 26397066
[10]	孟元光, 叶明侠. 卵巢癌肿瘤细胞减灭术的并发症及防治[J]. 中国实用妇科与产科杂志, 2021, 37(6):627-630. doi: 10.19538/j.fk2021060108.
[11]	卢淮武, 徐冬冬, 赵喜博, 等. 《2024 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2024, 40(2):187-197. doi: 10.19538/j.fk2024020113.
[12]	Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update[J]. Int J Gynaecol Obstet, 2021, 155(Suppl 1):61-85. doi: 10.1002/ijgo.13878.
[13]	郎景和. 肿瘤—手术—微创[J]. 中国微创外科杂志, 2023, 23(1):1-2. doi: 10.3969/j.issn.1009-6604.2023.01.001.
[14]	中国抗癌协会妇科肿瘤专业委员会. 卵巢癌腹腔镜技术诊治指南(2023年版)[J]. 中国实用妇科与产科杂志, 2023, 39(2):166-174. doi: 10.19538/j.fk2023020111.
[15]	Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease[J]. Ann Oncol, 2019, 30(5):672-705. doi: 10.1093/annonc/mdz062. pmid: 31987337
[16]	中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 肿瘤化疗导致的中性粒细胞减少诊治专家共识(2019年版)[J]. 中国医学前沿杂志(电子版), 2019,11(12):86-92. doi: 10.12037/YXQY.2019.12-11.
[17]	Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum[J]. Int J Gynaecol Obstet, 2014, 124(1):1-5. doi: 10.1016/j.ijgo.2013.10.001. pmid: 24219974
[18]	Stavros S, Potiris A, Machairiotis N, et al. Inguinal Lymph Node Metastasis as Sole Manifestation of Ovarian / Fallopian Tube Cancer: a Review of the Literature[J]. J Cancer, 2023, 14(17):3176-3181. doi: 10.7150/jca.88863. pmid: 37928416
[19]	Chalif J, Yao M, Gruner M, et al. Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer[J]. Gynecol Oncol, 2022, 165(1):90-96. doi: 10.1016/j.ygyno.2022.01.026. pmid: 35272875
[20]	Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies[J]. Jpn J Clin Oncol, 2015, 45(1):49-60. doi: 10.1093/jjco/hyu175. pmid: 25387732
[21]	Harter P, Sehouli J, Lorusso D, et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms[J]. N Engl J Med, 2019, 380(9):822-832. doi: 10.1056/NEJMoa1808424.